News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Blue-Zone Technologies Granted Canadian Patent For Central Collection Of Anesthetic Gases, Securing Their Leading Position In The Sector



11/7/2016 12:02:27 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

CONCORD, ON, Nov. 7, 2016 /CNW/ - Blue-Zone Technologies Ltd. ("Blue-Zone"), a multi-award-winning cleantech company, is pleased to announce the grant of an additional patent in Canada: Canadian Patent No. 2,772,776, granted October 25, 2016, Adsorbent and Systems and Methods for Recovery of Halogenated Hydrocarbons, with a 2009 priority date. This relates to Blue-Zone's Centralsorb® Anesthetic Recovery System, which enables recovery of waste anesthetic gases from a central location in a hospital. Earlier this year Blue-Zone announced a similar patent had been granted to it in the United States.

"Our technology enjoys a global profile, and the awarding of this patent reinforces Blue-Zone's position of worldwide leadership in the halogenated anesthetic gas collection, reclamation, and production sectors. As we are a Canadian company, the Canadian patent grant is extra special for us," says Dusanka Filipovic, P.Eng., co-inventor of Centralsorb®, and Founder, Vice Chair and President of the company. "Blue-Zone's patented technologies are a Cradle-to-Cradle® solution to a global problem, and align with today's international mandate by reducing a hospital's carbon footprint, protecting public health, and building valuable anesthetic production capacity, which is beneficial for the environment and mankind."  

About the Centralsorb® System

During a typical surgery 95% of the halogenated anesthetic drugs used are vented into the atmosphere. These anesthetics are very aggressive greenhouse gases. In North America, there are approximately 54,000 operating rooms, and annually those rooms can release the CO2 equivalent to well over two million cars. These toxic gases are stable, seven times heavier than air, tend to linger and amass in the area around a hospital for decades, and are an officially recognized occupational health and safety hazard. The use of anesthetic gases is forecast to grow globally by 10% to 15% per year, providing Blue-Zone's patented technology with a significant growth opportunity. 

Centralsorb®, as with Blue-Zone's other patented system, Deltasorb®, prevents the release of these greenhouse gases into the atmosphere and offers a significant value-add to merely collecting and stockpiling, and/or incinerating the waste. These captured anesthetics are subsequently extracted, liquefied and used as raw material in the production of new, validated generic anesthetics at Blue-Zone's facility. This ability to reprocess the recovered halogenated anesthetics which is unique to Blue-Zone and not provided by any other company, worldwide offers additional economic and security of supply benefits for hospitals that use Blue-Zone's patented technology. 

Blue-Zone currently services approximately 25% of Ontario operating rooms, many of them for over a decade. It is estimated that these operating rooms support about 200,000 surgical cases every year. In 2002, Blue-Zone installed Deltasorb®, the world's first-ever system to collect and capture anesthetic gases in a hospital operating room. Centralsorb® collects these same gases but from a central location, thus requiring no involvement from operating room staff. The efficacy of Centralsorb® in centralized conditions was confirmed through pilot testing at Sunnybrook Health Sciences Centre and the Cleveland Clinic Foundation in 2010. 

This new and exciting patent grant adds to Blue-Zone's growing patent portfolio, including previously granted US patents and other patents granted/pending around the world, related to the Centralsorb® system. The technology will allow for the central, efficient and validated recovery of the captured emissions of halogenated anesthetic drugs. It reinforces Blue-Zone's commitment to providing its hospital partners with best-in-class technology options, service, and support.

About Blue-Zone Technologies Ltd.

Blue-Zone is the world's first pioneer in the area of halogenated anesthetic collection, recovery, and pollution prevention, with aspects of its technology dating back to 1999. Blue-Zone's globally innovative technology for the capture and recovery of anesthetics was originally demonstrated with the Deltasorb® Canister System installed in operating rooms, developed in collaboration with the Department of Anesthesia at the University of Toronto. It has since evolved into the Centralsorb® System for collection at a central location in the hospital. Blue-Zone's technology solutions are currently collecting halogenated anesthetic drug emissions from approximately 25% of the operating rooms in Ontario, with expansion into additional hospitals in the US. With its unique ability to Prevent the Vent® of halogenated anesthetics and recover them for future medical use, Blue-Zone is Canada and the world's first and only company to offer a truly sustainable Cradle-to-Cradle® environmental service to deal with this serious situation.

Blue-Zone has won the following awards in Canada: Waste Minimization Gold Award 2010 (Recycling Council of Ontario), Innovator of the Year 2010 (PROFIT Magazine), Innovations@Work Award 2010 (Rogers and PROFIT Magazine), Red Herring Top 50 Award 2008, Canadian Innovation Award for Environmental Technologies 2005 (Canadian Manufacturers and Exporters). Blue-Zone has received recognition and financial support from the Industrial Research Assistance Program (IRAP), Sustainable Development Technology Canada (SDTC), and the Innovation Demonstration Fund (IDF).

SOURCE Blue-Zone Technologies Ltd.

CONCORD, ON, Nov. 7, 2016 /CNW/ - Blue-Zone Technologies Ltd. ("Blue-Zone"), a multi-award-winning cleantech company, is pleased to announce the grant of an additional patent in Canada: Canadian Patent No. 2,772,776, granted October 25, 2016, Adsorbent and Systems and Methods for Recovery of Halogenated Hydrocarbons, with a 2009 priority date. This relates to Blue-Zone's Centralsorb® Anesthetic Recovery System, which enables recovery of waste anesthetic gases from a central location in a hospital. Earlier this year Blue-Zone announced a similar patent had been granted to it in the United States.

"Our technology enjoys a global profile, and the awarding of this patent reinforces Blue-Zone's position of worldwide leadership in the halogenated anesthetic gas collection, reclamation, and production sectors. As we are a Canadian company, the Canadian patent grant is extra special for us," says Dusanka Filipovic, P.Eng., co-inventor of Centralsorb®, and Founder, Vice Chair and President of the company. "Blue-Zone's patented technologies are a Cradle-to-Cradle® solution to a global problem, and align with today's international mandate by reducing a hospital's carbon footprint, protecting public health, and building valuable anesthetic production capacity, which is beneficial for the environment and mankind."  

About the Centralsorb® System

During a typical surgery 95% of the halogenated anesthetic drugs used are vented into the atmosphere. These anesthetics are very aggressive greenhouse gases. In North America, there are approximately 54,000 operating rooms, and annually those rooms can release the CO2 equivalent to well over two million cars. These toxic gases are stable, seven times heavier than air, tend to linger and amass in the area around a hospital for decades, and are an officially recognized occupational health and safety hazard. The use of anesthetic gases is forecast to grow globally by 10% to 15% per year, providing Blue-Zone's patented technology with a significant growth opportunity. 

Centralsorb®, as with Blue-Zone's other patented system, Deltasorb®, prevents the release of these greenhouse gases into the atmosphere and offers a significant value-add to merely collecting and stockpiling, and/or incinerating the waste. These captured anesthetics are subsequently extracted, liquefied and used as raw material in the production of new, validated generic anesthetics at Blue-Zone's facility. This ability to reprocess the recovered halogenated anesthetics which is unique to Blue-Zone and not provided by any other company, worldwide offers additional economic and security of supply benefits for hospitals that use Blue-Zone's patented technology. 

Blue-Zone currently services approximately 25% of Ontario operating rooms, many of them for over a decade. It is estimated that these operating rooms support about 200,000 surgical cases every year. In 2002, Blue-Zone installed Deltasorb®, the world's first-ever system to collect and capture anesthetic gases in a hospital operating room. Centralsorb® collects these same gases but from a central location, thus requiring no involvement from operating room staff. The efficacy of Centralsorb® in centralized conditions was confirmed through pilot testing at Sunnybrook Health Sciences Centre and the Cleveland Clinic Foundation in 2010. 

This new and exciting patent grant adds to Blue-Zone's growing patent portfolio, including previously granted US patents and other patents granted/pending around the world, related to the Centralsorb® system. The technology will allow for the central, efficient and validated recovery of the captured emissions of halogenated anesthetic drugs. It reinforces Blue-Zone's commitment to providing its hospital partners with best-in-class technology options, service, and support.

About Blue-Zone Technologies Ltd.

Blue-Zone is the world's first pioneer in the area of halogenated anesthetic collection, recovery, and pollution prevention, with aspects of its technology dating back to 1999. Blue-Zone's globally innovative technology for the capture and recovery of anesthetics was originally demonstrated with the Deltasorb® Canister System installed in operating rooms, developed in collaboration with the Department of Anesthesia at the University of Toronto. It has since evolved into the Centralsorb® System for collection at a central location in the hospital. Blue-Zone's technology solutions are currently collecting halogenated anesthetic drug emissions from approximately 25% of the operating rooms in Ontario, with expansion into additional hospitals in the US. With its unique ability to Prevent the Vent® of halogenated anesthetics and recover them for future medical use, Blue-Zone is Canada and the world's first and only company to offer a truly sustainable Cradle-to-Cradle® environmental service to deal with this serious situation.

Blue-Zone has won the following awards in Canada: Waste Minimization Gold Award 2010 (Recycling Council of Ontario), Innovator of the Year 2010 (PROFIT Magazine), Innovations@Work Award 2010 (Rogers and PROFIT Magazine), Red Herring Top 50 Award 2008, Canadian Innovation Award for Environmental Technologies 2005 (Canadian Manufacturers and Exporters). Blue-Zone has received recognition and financial support from the Industrial Research Assistance Program (IRAP), Sustainable Development Technology Canada (SDTC), and the Innovation Demonstration Fund (IDF).

SOURCE Blue-Zone Technologies Ltd.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES